Drug Price Transparency Act
Bill journey · stage 1 of 5
Just introduced
What it doesSummary introduced in house (Apr 4, 2019)
Drug Price Transparency Act
This bill requires certain manufacturers of drugs that are covered under Medicare medical services to report pricing information to the Centers for Medicare & Medicaid Services. Specifically, manufacturers of such drugs that do not have rebate agreements under the Medicaid Drug Rebate Program must report similar information as is required under the program, including average sales price, total units, and wholesale acquisition cost. Manufacturers that fail to comply or that report false information are subject to civil penalties.
What just happenedMay 21, 2019
Subcommittee Hearings Held.
Who’s behind it
- Introduced in HouseApr 4, 2019
- May 21, 2019Committee
Subcommittee Hearings Held.
Health Subcommittee - Apr 5, 2019Committee
Referred to the Subcommittee on Health.
Health Subcommittee - Apr 4, 2019Committee
Referred to the Subcommittee on Health.
Ways and Means CommitteeHealth Subcommittee - Apr 4, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Ways and Means Committee - Apr 4, 2019IntroReferralH11100
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Energy and Commerce Committee - Apr 4, 2019IntroReferralIntro-H
Introduced in House
- Apr 4, 2019IntroReferral1000
Introduced in House